ABT vs RLAY · P/E 25, rev $44.33B vs rev $3.4M
Abbott Laboratories (ABT) versus Relay Therapeutics Inc (RLAY) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
Relay Therapeutics Inc (RLAY) is a biotechnology company listed on NASDAQ.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported RLAY revenue for 2026-06-30 was $3.4M. Net income was -$157.0M. Revenue was up 11.7% from 2026-03-31 to 2026-06-30. RLAY currently screens at market cap $3.39B.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. RLAY currently screens at market cap $3.39B.
Not investment advice. Open the ABT and RLAY stock pages for the full models.
Not investment advice.